|
Volumn 3, Issue 5, 1994, Pages 309-319
|
Costs, effects and C/E‐ratios alongside a clinical trial
|
Author keywords
anakinra; confidence intervals; cost effectiveness ratio; Economic appraisal; rhIL lra; sepsis syndrome
|
Indexed keywords
IL1RN PROTEIN, HUMAN;
INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
SIALOGLYCOPROTEIN;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
ECONOMICS;
HUMAN;
RANDOMIZED CONTROLLED TRIAL;
SOCIOECONOMICS;
STATISTICAL MODEL;
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;
COST-BENEFIT ANALYSIS;
HUMANS;
INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN;
MODELS, ECONOMIC;
RANDOMIZED CONTROLLED TRIALS;
SIALOGLYCOPROTEINS;
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;
VALUE OF LIFE;
|
EID: 0028509556
PISSN: 10579230
EISSN: 10991050
Source Type: Journal
DOI: 10.1002/hec.4730030505 Document Type: Article |
Times cited : (793)
|
References (18)
|